艾伯維
ABBV211.960USD
-6.080-2.79%
收盤 11/03, 16:00（美東）報價延遲15分鐘
374.42B總市值
158.79本益比TTM
關於 艾伯維 公司
艾伯維為一家多元、科研驅動的生物製藥領跑者，專注藥物與療法的研發、生產、商業化與銷售。公司透過遍布美洲、歐洲與亞洲的生產與行銷渠道，將療法推向逾一百七十五個市場 。產品線橫跨免疫學、腫瘤學、醫美、神經科學、眼科護理及其他專科。免疫學覆蓋風濕、皮膚與腸胃疾病；腫瘤學聚焦急性髓系、急性淋系、慢性淋系白血病及瀰漫性大B細胞淋巴瘤；神經領域涵括帕金森、偏頭痛、運動與精神障礙及阿茲海默；眼科護理面向慢性乾眼、青光眼、老年性視網膜退化與屈光不正；醫美業務提供 Botox Cosmetic、The Juvederm Collection of Fillers 等注射產品。管線中 NX-13 用於潰瘍性結腸炎與克隆氏病治療；CEL383 鎖定炎症性腸病；ALIA-1758 瞄準阿茲海默患者群體。
艾伯維簡介
公司代碼ABBV
公司名稱AbbVie Inc
上市日期Jan 02, 2013
CEOMr. Robert A. Michael, CPA
員工數量55000
證券類型Ordinary Share
年結日Jan 02
公司地址1 N Waukegan Rd
城市NORTH CHICAGO
上市交易所NYSE Consolidated
國家United States of America
郵編60064
電話18479327900
網址https://www.abbvie.com/
公司代碼ABBV
上市日期Jan 02, 2013
CEOMr. Robert A. Michael, CPA
艾伯維公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Azita Saleki-Gerhardt, Ph.D.
Dr. Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Chief Operations Officer
Executive Vice President, Chief Operations Officer
183.77K
--
Mr. Thomas C. (Tom) Freyman, CPA
Mr. Thomas C. (Tom) Freyman, CPA
Independent Director
Independent Director
134.63K
+0.90%
Mr. Edward J. (Ed) Rapp
Mr. Edward J. (Ed) Rapp
Independent Director
Independent Director
42.95K
+2.88%
Dr. Roopal Thakkar, M.D.
Dr. Roopal Thakkar, M.D.
Executive Vice President - Research & Development, Chief Scientific Officer
Executive Vice President - Research & Development, Chief Scientific Officer
42.28K
+16.15%
Ms. Roxanne S. Austin, CPA
Ms. Roxanne S. Austin, CPA
Lead Independent Director
Lead Independent Director
38.46K
+3.23%
Dr. Robert J. Alpern, M.D.
Dr. Robert J. Alpern, M.D.
Independent Director
Independent Director
35.65K
+3.49%
Mr. Frederick H. (Rick) Waddell
Mr. Frederick H. (Rick) Waddell
Independent Director
Independent Director
28.96K
+4.33%
Ms. Melody B. Meyer
Ms. Melody B. Meyer
Independent Director
Independent Director
16.50K
+7.87%
Mr. Timothy J. Richmond
Mr. Timothy J. Richmond
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
6.13K
-77.61%
Ms. Jennifer L. Davis
Ms. Jennifer L. Davis
Independent Director
Independent Director
2.52K
+91.00%
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Azita Saleki-Gerhardt, Ph.D.
Dr. Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Chief Operations Officer
Executive Vice President, Chief Operations Officer
183.77K
--
Mr. Thomas C. (Tom) Freyman, CPA
Mr. Thomas C. (Tom) Freyman, CPA
Independent Director
Independent Director
134.63K
+0.90%
Mr. Edward J. (Ed) Rapp
Mr. Edward J. (Ed) Rapp
Independent Director
Independent Director
42.95K
+2.88%
Dr. Roopal Thakkar, M.D.
Dr. Roopal Thakkar, M.D.
Executive Vice President - Research & Development, Chief Scientific Officer
Executive Vice President - Research & Development, Chief Scientific Officer
42.28K
+16.15%
Ms. Roxanne S. Austin, CPA
Ms. Roxanne S. Austin, CPA
Lead Independent Director
Lead Independent Director
38.46K
+3.23%
Dr. Robert J. Alpern, M.D.
Dr. Robert J. Alpern, M.D.
Independent Director
Independent Director
35.65K
+3.49%
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
Immunology-SKYRIZI
4.42B
28.20%
Immunology-RINVOQ
2.03B
12.93%
Immunology-HUMIRA
1.18B
7.52%
Hematologic Oncology-IMBRUVICA
965.00M
6.15%
Neuroscience-Botox Therapeutic
928.00M
5.92%
其他
6.16B
39.27%
地區USD
名稱
營收
佔比
United States
11.34B
72.31%
International
3.48B
22.18%
All other countries
603.00M
3.84%
Collaboration revenue
260.00M
1.66%
業務
地區
業務USD
名稱
營收
佔比
Immunology-SKYRIZI
4.42B
28.20%
Immunology-RINVOQ
2.03B
12.93%
Immunology-HUMIRA
1.18B
7.52%
Hematologic Oncology-IMBRUVICA
965.00M
6.15%
Neuroscience-Botox Therapeutic
928.00M
5.92%
其他
6.16B
39.27%
股東統計
更新時間: 8月17日 週日
更新時間: 8月17日 週日
持股股東
股東類型
持股股東
持股股東
佔比
The Vanguard Group, Inc.
9.99%
BlackRock Institutional Trust Company, N.A.
5.21%
State Street Investment Management (US)
4.53%
Geode Capital Management, L.L.C.
2.22%
JP Morgan Asset Management
2.12%
其他
75.93%
持股股東
持股股東
佔比
The Vanguard Group, Inc.
9.99%
BlackRock Institutional Trust Company, N.A.
5.21%
State Street Investment Management (US)
4.53%
Geode Capital Management, L.L.C.
2.22%
JP Morgan Asset Management
2.12%
其他
75.93%
股東類型
持股股東
佔比
Investment Advisor
43.55%
Investment Advisor/Hedge Fund
19.97%
Research Firm
3.07%
Bank and Trust
2.30%
Pension Fund
2.21%
Sovereign Wealth Fund
1.40%
Hedge Fund
1.28%
Insurance Company
0.69%
Family Office
0.20%
其他
25.33%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
5286
1.32B
74.49%
-7.96M
2025Q2
5271
1.32B
74.93%
+10.38M
2025Q1
5332
1.32B
74.90%
+11.71M
2024Q4
5219
1.31B
74.47%
+8.91M
2024Q3
4974
1.30B
73.54%
-7.44M
2024Q2
4916
1.30B
73.53%
+2.27M
2024Q1
4930
1.29B
72.58%
-1.47M
2023Q4
4882
1.28B
72.31%
-1.48M
2023Q3
4694
1.27B
71.87%
-12.06M
2023Q2
4688
1.26B
71.51%
-30.42M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
176.50M
9.99%
+3.35M
+1.94%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
92.10M
5.21%
+1.07M
+1.18%
Jun 30, 2025
State Street Investment Management (US)
80.02M
4.53%
+61.16K
+0.08%
Jun 30, 2025
Geode Capital Management, L.L.C.
39.18M
2.22%
+924.76K
+2.42%
Jun 30, 2025
JP Morgan Asset Management
37.47M
2.12%
+1.87M
+5.24%
Jun 30, 2025
Charles Schwab Investment Management, Inc.
26.78M
1.52%
+1.52M
+6.01%
Jun 30, 2025
Capital Research Global Investors
25.27M
1.43%
-8.24M
-24.60%
Jun 30, 2025
Morgan Stanley Smith Barney LLC
23.51M
1.33%
+254.93K
+1.10%
Jun 30, 2025
Norges Bank Investment Management (NBIM)
23.10M
1.31%
-1.99M
-7.94%
Jun 30, 2025
Fidelity Management & Research Company LLC
19.65M
1.11%
-1.78M
-8.30%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月2日 週日
更新時間: 11月2日 週日
機構名稱
佔比
iShares ESG Aware MSCI USA Value ETF
12.4%
Proshares Ultra Health Care
8.16%
iShares U.S. Healthcare ETF
8.12%
Health Care Select Sector SPDR Fund
8.11%
First Trust NASDAQ Pharmaceuticals ETF
8.08%
JPMorgan Healthcare Leaders ETF
7.39%
Fidelity MSCI Health Care Index ETF
7.06%
Themes US Cash Flow Champions ETF
6.78%
Simplify Health Care ETF
6.75%
iShares Core High Dividend ETF
6.32%
查看更多
iShares ESG Aware MSCI USA Value ETF
佔比12.4%
Proshares Ultra Health Care
佔比8.16%
iShares U.S. Healthcare ETF
佔比8.12%
Health Care Select Sector SPDR Fund
佔比8.11%
First Trust NASDAQ Pharmaceuticals ETF
佔比8.08%
JPMorgan Healthcare Leaders ETF
佔比7.39%
Fidelity MSCI Health Care Index ETF
佔比7.06%
Themes US Cash Flow Champions ETF
佔比6.78%
Simplify Health Care ETF
佔比6.75%
iShares Core High Dividend ETF
佔比6.32%
分紅派息
近5年累計派現
48.58B
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
Oct 30, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Feb 14, 2025 going ex on Jan 15, 2025
Jan 15, 2025
Feb 14, 2025
Jan 15, 2025
Sep 06, 2024
ABBV.NB Final Cash Dividend of gross USD 1.55 paid on Nov 15, 2024 going ex on Oct 15, 2024 with reinvestment option
Oct 15, 2024
Nov 15, 2024
Oct 15, 2024
Jun 21, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option
Jul 15, 2024
Aug 15, 2024
Jul 15, 2024
Feb 15, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on May 15, 2024 going ex on Apr 12, 2024 with reinvestment option
Apr 15, 2024
May 15, 2024
Apr 12, 2024
Oct 27, 2023
ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Feb 15, 2024 going ex on Jan 12, 2024 with reinvestment option
Jan 16, 2024
Feb 15, 2024
Jan 12, 2024
Sep 11, 2023
ABBV.NB Final Cash Dividend of gross USD 1.48 paid on Nov 15, 2023 going ex on Oct 12, 2023 with reinvestment option
Oct 13, 2023
Nov 15, 2023
Oct 12, 2023
Jun 22, 2023
ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on Aug 15, 2023 going ex on Jul 13, 2023 with reinvestment option
Jul 14, 2023
Aug 15, 2023
Jul 13, 2023
Feb 16, 2023
ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on May 15, 2023 going ex on Apr 13, 2023 with reinvestment option
Apr 14, 2023
May 15, 2023
Apr 13, 2023
Oct 28, 2022
ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on Feb 15, 2023 going ex on Jan 12, 2023 with reinvestment option
Jan 13, 2023
Feb 15, 2023
Jan 12, 2023
Sep 09, 2022
ABBV.NB Final Cash Dividend of gross USD 1.41 paid on Nov 15, 2022 going ex on Oct 13, 2022 with reinvestment option
Oct 14, 2022
Nov 15, 2022
Oct 13, 2022
查看更多
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
